NO2399993T3 - - Google Patents

Info

Publication number
NO2399993T3
NO2399993T3 NO10743584A NO10743584A NO2399993T3 NO 2399993 T3 NO2399993 T3 NO 2399993T3 NO 10743584 A NO10743584 A NO 10743584A NO 10743584 A NO10743584 A NO 10743584A NO 2399993 T3 NO2399993 T3 NO 2399993T3
Authority
NO
Norway
Application number
NO10743584A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2399993T3 publication Critical patent/NO2399993T3/no

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO10743584A 2009-02-20 2010-02-19 NO2399993T3 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009037750 2009-02-20
PCT/JP2010/001100 WO2010095455A1 (ja) 2009-02-20 2010-02-19 低免疫原性ストレプトアビジンおよびその利用

Publications (1)

Publication Number Publication Date
NO2399993T3 true NO2399993T3 (zh) 2018-02-17

Family

ID=42633742

Family Applications (1)

Application Number Title Priority Date Filing Date
NO10743584A NO2399993T3 (zh) 2009-02-20 2010-02-19

Country Status (7)

Country Link
US (1) US8546537B2 (zh)
EP (1) EP2399993B1 (zh)
JP (1) JP5472754B2 (zh)
CN (1) CN102325884B (zh)
CA (1) CA2753048C (zh)
NO (1) NO2399993T3 (zh)
WO (1) WO2010095455A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105073770B (zh) * 2012-11-16 2019-08-06 Iba股份有限公司 链霉亲和素突变蛋白及其使用方法
JP6178586B2 (ja) 2013-02-20 2017-08-09 サヴィッド・セラピューティックス株式会社 ビオチン改変体、ストレプトアビジン変異体およびそれらの利用
JP6096371B2 (ja) * 2014-02-18 2017-03-15 サヴィッド・セラピューティックス株式会社 ビオチン改変体、ストレプトアビジン変異体およびそれらの利用
JP2018530605A (ja) * 2015-09-23 2018-10-18 ヨーロピアン モレキュラー バイオロジー ラボラトリーＥｕｒｏｐｅａｎ Ｍｏｌｅｃｕｌａｒ Ｂｉｏｌｏｇｙ Ｌａｂｏｒａｔｏｒｙ プロテアーゼ抵抗性のストレプトアビジン
WO2018097239A1 (ja) 2016-11-25 2018-05-31 サヴィッド・セラピューティックス株式会社 クリアリングエージェント
CN112243441A (zh) 2018-05-30 2021-01-19 国立大学法人东京大学 经卤化的生物素修饰二聚体及其应用
JPWO2021210573A1 (zh) 2020-04-14 2021-10-21
AU2021369744B2 (en) 2020-10-30 2024-07-11 Tod SPEER Oligonucleotide-based therapeutics and uses thereof
EP4382609A1 (en) 2021-07-29 2024-06-12 The University of Tokyo Fusion protein between antigen-binding molecule and streptavidin variant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4135543A1 (de) 1991-10-28 1993-04-29 Boehringer Mannheim Gmbh Rekombinantes core-streptavidin
CA2134239C (en) 1992-06-09 2004-11-23 Donald B. Axworthy Pretargeting methods and compounds
CA2222035A1 (en) 1995-04-11 1997-03-27 Trustees Of Boston University Streptavidin mutants
BR9807214A (pt) * 1997-02-10 2000-04-25 Ca Minister Agriculture & Food Método para melhoramento das caracterìsticas de armazenamento a frio do tubérculo de batata
CA2376192A1 (en) * 1999-06-07 2000-12-14 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US20030143233A1 (en) 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US7148051B2 (en) * 2004-08-16 2006-12-12 E. I. Du Pont De Nemours And Company Production of 3-hydroxycarboxylic acid using nitrilase
JP5117765B2 (ja) 2007-05-28 2013-01-16 国立大学法人 東京大学 抗ｒｏｂｏ１抗体を含むｐｅｔ用腫瘍診断剤

Also Published As

Publication number Publication date
EP2399993A9 (en) 2012-07-18
CN102325884B (zh) 2013-11-20
CA2753048C (en) 2015-11-03
US20120039879A1 (en) 2012-02-16
EP2399993A1 (en) 2011-12-28
EP2399993B1 (en) 2017-09-20
CN102325884A (zh) 2012-01-18
JP5472754B2 (ja) 2014-04-16
EP2399993A4 (en) 2013-07-03
US8546537B2 (en) 2013-10-01
CA2753048A1 (en) 2010-08-26
WO2010095455A1 (ja) 2010-08-26
JPWO2010095455A1 (ja) 2012-08-23

Similar Documents

Publication Publication Date Title
BR112012008267A2 (zh)
BR112012003062A2 (zh)
BR112012008195A2 (zh)
BRPI0925311A2 (zh)
BRPI0924307A2 (zh)
BR122021004633A2 (zh)
BR112012003080A2 (zh)
BR122017024704A2 (zh)
BR112012000665A2 (zh)
BR112012009446A2 (zh)
BR112012007656A2 (zh)
BR112012001263A2 (zh)
BR122019005883A2 (zh)
BR112012002627A2 (zh)
BRPI1004942A2 (zh)
BRPI0924534A2 (zh)
BR112012007654A2 (zh)
BR112012007672A2 (zh)
BR112012005951A2 (zh)
BRPI1014557A2 (zh)
BR122017013721A2 (zh)
BR112012009404A2 (zh)
BRPI0924617A2 (zh)
BR112012007671A2 (zh)
BRPI0925022A2 (zh)